John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
MacLeod S, Musich S, Keown K, Yeh CS. Practical technological solutions to support successful aging. J Aging Geriatr Med. 2019 Aug 14;3(1).
MacLeod S, Musich S, Ruiz JM, Yeh CS. Perceptions of aging and their impact on older adults' health outcomes. J Aging Geriatr Med. 2019 Apr 30;3(1).
MacLeod S, Musich S, Parikh RB, Hawkins K, Keown K, Yeh CS. Examining approaches to address loneliness and social isolation among older adults. J Aging Geriatr Med. 2018 Feb 8;2(1). doi: 10.4172/2576-3946.1000115
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.